(Q37631965)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19909915%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

review article

1 reference

title

Multiple system atrophy: an update (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19909915%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

main subject

multiple system atrophy

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19909915%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Gregor Wenning

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19909915%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Philipp Bücke

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19909915%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Susanne Duerr

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19909915%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19909915%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19909915%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19909915%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19909915%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1172-1178

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19909915%20AND%20SRC:MED&resulttype=core&format=json

Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Protein aggregation mechanisms in synucleinopathies: commonalities and differences

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Consensus statement on the diagnosis of multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Second consensus statement on the diagnosis of multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Survival in multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Potential outcome measures and trial design issues for multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Progression of parkinsonism in multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Early development of autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

The European Multiple System Atrophy-Study Group (EMSA-SG).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Proposed neuroimaging criteria for the diagnosis of multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Grading of neuropathology in multiple system atrophy: proposal for a novel scale

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

TPPP/p25: from unfolded protein to misfolding disease: prediction and experiments

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Multiple system atrophy: a primary oligodendrogliopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Multiple system atrophy: alpha-synuclein and neuronal degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

An autopsy case of early ("minimal change") olivopontocerebellar atrophy (multiple system atrophy-cerebellar).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

P25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Heredity in multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Definite multiple system atrophy in a German family.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

SNCA variants are associated with increased risk for multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Epidemiological evidence on multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Risk factors of multiple system atrophy: a case-control study in French patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Microglial activation mediates neurodegeneration related to oligodendroglial α-synucleinopathy: Implications for multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Recent developments in multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Rasagiline is neuroprotective in a transgenic model of multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Animal models of multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Striatal transplantation for multiple system atrophy--are grafts affected by alpha-synucleinopathy?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970288-1

7 January 2021

10.1016/S1474-4422(09)70288-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19909915%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference